Company · Boonton · United States
Enteris Biopharma (United States)
- Research works
- 1 ▼ 24% vs 2013–17
- Citations
- 23 19.7 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 29% world 28%
Not ranked overall: Enteris Biopharma (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Enteris Biopharma (United States) publish most on?
By volume in 2022–2025: Pharmaceutical studies and practices.
- 1 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
openly available28.6%not open71.4%
World: 28% of research is openly available.
with international co-authors100.0%
World: 19% is written across borders.
How has Enteris Biopharma (United States)'s research output changed?
Output in 2018–2022 was 24% lower than in 2013–2017.
Other research institutions in Boonton
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.